Form 4: Design Therapeutics COO Awarded Stock Options

Design Therapeutics' Chief Operating Officer, Sean Jeffries, was granted stock options for 260,000 shares on January 2, 2025.

Summary

• Sean Jeffries, the Chief Operating Officer of Design Therapeutics, was granted stock options to purchase 260,000 shares of the company's common stock.
• The options have an exercise price of $6.17 per share.
• The options vest over a period of time, with 20% vesting on January 1, 2026, and the remaining 80% vesting in equal monthly installments over the following 36 months.
• The options expire on January 1, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The granting of stock options to the COO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the COO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in the biotech industry.
• The vesting schedule of the options is typical, with a portion vesting initially and the remainder vesting over a period of years.
• The exercise price is likely set at or near the market price of the stock at the time of the grant, which is standard practice.

Stakeholder Impact

• The stock option grant may be viewed positively by shareholders as it incentivizes the COO to increase the company's value.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

stock options, executive compensation, insider trading, Design Therapeutics, DSGN, Sean Jeffries, Chief Operating Officer